Targeted Oncology

, Volume 2, Issue 1, pp 39–47

Targeted therapies in T-cell malignancies

Review

DOI: 10.1007/s11523-006-0035-0

Cite this article as:
Leung, A.Y.H. & Liang, R. Targ Oncol (2007) 2: 39. doi:10.1007/s11523-006-0035-0
  • 29 Downloads

Abstract

The World Health Organization (WHO) has classified T-cell malignancies into mature T-cell and natural killer (NK)-cell neoplasms and precursor T-cell lymphoblastic lymphoma/leukemia. Mature T-cell lymphomas, alternatively known as peripheral T-cell lymphomas (PTCLs), are rare diseases with extremely heterogeneous clinicopathologic profiles. Treatment protocols for PTCL are mostly adapted from those used for B-cell lymphomas, but the prognosis is generally worse. More recently, monoclonal antibodies, including alemtuzumab (Campath-1H, anti-CD52) and denileukin diftitox (Ontak, anti-CD25), have been shown to be effective in the treatment of T-prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma. The unique association of human T-cell lymphotropic virus in adult T-cell lymphoma/leukemia has also led to the use of anti-viral agents in this disease with significant improvement in outcome. A number of novel monoclonal antibodies and histone deacetylase inhibitors are also being evaluated. The roles of these targeted therapies as first-line treatment or in combination with conventional chemotherapy and the roles of autologous and allogeneic hematopoietic stem cell transplantation in PTCL need further investigation.

Keywords

T-cell lymphomas/leukemiaAlemtuzumabDenileukin diftitoxMonoclonal antibodiesHistone deacetylase inhibitorsAnti-viral therapy

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Division of Hematology and Bone Marrow Transplantation, Department of Medicine, Queen Mary HospitalUniversity of Hong KongHong KongPeople’s Republic of China
  2. 2.Queen Mary Hospital, Department of Medicine, K417, K BlockUniversity of Hong KongHong Kong SARPeople’s Republic of China